PharmaTelevision - Biosceptre: Cliff Holloway discusses developing their antibodies to nf-P2X7 for therapeutic and diagnostic applications in cancer

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Biosceptre: Cliff Holloway discusses developing their antibodies to nf-P2X7 for therapeutic and diagnostic applications in cancer

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to Cliff Holloway, CEO of BioSceptre.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Platform technology and core programs

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here at AusBiotech's convention in Adelaide. On this show I have Cliff Holloway, who is CEO of a company called Biosceptre International Limited which is based in Sydney, welcome.

Cliff Holloway:

Thank you.

Fintan Walton:

So Cliff, could you tell us a little bit about Biosceptre International ?

Cliff Holloway:

Yes, so our intellectual property and our platform is based on a novel cancer target which we refer to as non-functional P2X7, so in a normal cell life cycle P2X7 is expressed in the cell surface and conform an apoptotic pore and what Biosceptre has identified is a structural or confirmational change in this receptor that renders the receptor unable to form this apoptotic pore and we've identified this target in over 20 different cancer indications to-date.

Fintan Walton:

Okay, so it's effect in effect a biomarker?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Cliff Holloway

Chief Executive Officer

At the time of recording this PTV interview Cliff Holloway serves as Chief Executive Officer of Biosceptre International Limited. Dr Cliff Holloway has over 20 years experience in the commercialization of emerging technologies and has been instrumental in the direction and expansion of company operations and joint ventures in the US, Europe and Asia. Following his early career in clinical research with Eli Lilly and Novartis he has since held senior and executive management positions in drug discovery platform, software technology and biopharmaceutical companies, including for Molecular Simulations (now Accelrys), Superscape and Pharmacopeia Drug Discovery Inc. He most recently held the position of Vice President, Business Development at Arana Therapeutics (now Cephalon) with responsibility for driving the company's commercialization strategy through the partnering of antibody development programs and acquisition of additional assets and technologies.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

Biosceptre International Limited

Biosceptre International Limited is dedicated to the discovery and development of a new and novel cancer target and related therapies for the treatment of a broad range of cancer indications. The company's core platform and Intellectual Property position is based on the discovery of a novel cancer biomarker known as 'non-functional' P2X7 (nf-P2X7) which has been identified in over 20 cancer indications tested to date. The company's core focus is to validate nf-P2X7 as a therapeutic target and develop antibody products for use in proof of concept clinical studies in humans. Biosceptre is an unlisted public company founded in 2001 (Sydney).